Related Experiment Video
Updated: Jun 19, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
TRPV6 alleles do not influence prostate cancer progression
Thorsten Kessler1, Ulrich Wissenbach, Rainer Grobholz
1Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, Homburg/Saar, Germany. kesslerthorsten@googlemail.com
The transient receptor potential, subfamily V, member 6 (TRPV6) genotype does not correlate with prostate cancer onset, Gleason score, or tumor stage, despite its altered expression in aggressive forms of the disease.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Transient receptor potential, subfamily V, member 6 (TRPV6) is a Ca(2+) selective cation channel.
- TRPV6 transcripts are found in advanced prostate cancer but not in healthy tissue.
- Two allelic variants, TRPV6a and TRPV6b, exist for the human TRPV6 gene.
Purpose of the Study:
- To investigate the correlation between the trpv6a allele and prostate cancer onset.
- To determine the association of the trpv6a allele with Gleason score and tumor stage.
Main Methods:
- Genotyping of TRPV6 gene single nucleotide polymorphisms (SNPs) using restriction fragment length polymorphism or sequencing.
- RT-PCR to analyze RNA isolated from prostate tissue.
- Chi-Square test for data analysis.
Main Results:
- The TRPV6b genotype predominated (86%) in healthy individuals; no homozygous TRPV6a carriers were found.
- TRPV6b allele frequency was 87% in prostate adenocarcinoma samples, with no correlation to Gleason score or tumor stage.
- Allele frequencies in healthy individuals and prostate cancer patients were not significantly different.
Conclusions:
- TRPV6 allele frequencies do not differ significantly between healthy individuals and prostate cancer patients.
- TRPV6 genotype is not correlated with prostate cancer onset, Gleason score, or tumor stage.
- Despite altered expression correlating with aggressive prostate cancer, the TRPV6 genotype lacks predictive value for disease characteristics.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

